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Undercarboxylated osteocalcin (ucoc) could be a biomarker of glucose disturbances and cardiovascular 
risk. our study aimed to determine the association between serum levels of ucoc and cardiovascular 
risk in metabolic syndrome (MetS) patients and to analyse its potential role as estimator of type 2 
diabetes (T2D) risk in this population. This cross-sectional study included 235 patients with MetS, 
53.2% women, aged 55–75 years. Circulating ucOC levels were measured by ELISA. Cardiovascular risk 
was determined as Z-score of the diagnostic criteria for MetS (CV-ZS). Linear regression model was 
performed to analyse the association between circulating ucoc and cV-ZS. A receiver operating curve 
(ROC) was performed to analyse the usefulness of ucOC as T2D risk estimator. Patients above the CV-ZS 
median showed significant lower ucOC levels. We found an inverse association between ucOC levels and 
CV-ZS in MetS patients without T2D. Patients with ucOC levels below the 25th percentile showed worse 
cardiometabolic profile and higher cardiovascular and T2D risk. The area under the curve performed 
better when ucOC levels were included along with the classic T2D risk factors. The measurement of 
circulating ucOC could be a useful tool to identify increased cardiovascular and T2D risk in MetS patients 
without T2D.
Current lifestyle is causing a remarkable increase in overweight up to epidemic numbers globally1. In Spain, over 
60% of the adult population is overweight or obese2. According to this trend, an increase of 16% in the number 
of cases is estimated by 2030 associated with a 58% increase in direct healthcare costs3. A large body of evidence 
has shown that all-cause mortality, and especially cardiovascular-related mortality, is associated with an increased 
central adiposity and overweight4. Visceral obesity in conjunction with other disorders, such as dyslipidaemia, 
hypertension and fasting hyperglycaemia lead to the metabolic syndrome (MetS), conferring thus a larger risk of 
developing cardiovascular disease (CVD)5.
An association between osteoporosis, CVD and cardiovascular-related mortality has been reported6,7. The 
common risk factors involved in bone fragility and CVD could partially explain this association. Therefore, the 
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imbalance between bone formation and resorption occurring in bone disorders could play a role in the develop-
ment of vascular complications8. Recent data suggest an influence of bone metabolism on energy balance, which 
may be relevant for CVD9. In this regard, angiogenesis plays a major role in bone fracture healing and repair10 and 
changes in the local vasculature are associated with the progression of numerous conditions affecting bone, such 
as osteoporosis, rheumatoid arthritis, bone cancer and metastasis11.
Bone-related proteins, such as osteocalcin (OC), are of special interest for the study of CVD. OC is a small 
non-collagenous protein of 49 amino acids produced exclusively by osteoblasts and it is one of the most abundant 
proteins in bone. OC has been classically linked to bone mineralisation12. Moreover, the role of OC as an endo-
crine hormone involved in the regulation of energy metabolism has been demonstrated in vitro and in animal 
models13. Most OC is incorporated into the extracellular bone matrix; however, its undercarboxylated fraction 
(ucOC) is released into the bloodstream. UcOC can act directly on pancreatic beta cells and on adipocytes, reg-
ulating insulin secretion and insulin sensitivity. These findings have assigned a new role to the bone as an endo-
crine organ with extra-skeletal functions14.
Several studies in humans have evaluated the relationship between circulating levels of total OC and impaired 
glucose metabolism15, pointing to OC as a marker that could predict changes in glucose homeostasis16.
Moreover, OC has been linked to atherosclerotic parameters, such as brachial-ankle pulse wave velocity and 
intima-media thickness in patients with T2D17 and previous atherosclerotic disease8.
Despite the large evidence about OC as a metabolic regulator18–20, the involvement of ucOC in cardiovascular 
risk in MetS patients remains unclear. This occurs because most of the studies in this regard have analysed the 
relationship between ucOC and individual cardiovascular parameters. To date, no studies evaluating the role 
of ucOC serum levels as a potential biomarker of cardiovascular risk determined as a global score are available.
In this context, the aims of the present study were: 1. To determine the serum levels of ucOC in adults with 
MetS in order to analyse the association between ucOC and cardiovascular risk scores. 2. To provide information 
on the possible usefulness of circulating ucOC level as estimator of T2D risk in this population.
Results
characteristics of the study population. The clinical characteristics of the entire population according 
to the cardiovascular risk Z-score (CV-ZS) for 50th percentile (P50) are summarised in Table 1.
Both groups (<P50 CV-ZS and >P50 CV-ZS) were comparable in age and sex. As expected, the MetS 
patients with higher cardiovascular risk (>P50 CV-ZS) showed significantly worse cardiometabolic profile in 
terms of body mass index (BMI), waist circumference (WC), blood pressure (BP), fasting plasma glucose (FPG), 
high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) levels and glycated haemoglobin (HbA1c). In 
addition, these patients showed significantly lower serum levels of ucOC than the group with CV-ZS below P50.
Considering cardiovascular risk scores estimated by Framingham and REGICOR, we found significant differ-
ences between groups according to P50 of CV-ZS, finding a significant positive correlation between CV-ZS and 
Framingham and REGICOR scores (Fig. 1).
We found significantly higher percentage of patients with prevalent T2D in the group above P50 of CV-ZS 
than in the group below P50 of CV-ZS.
Association between serum levels of ucoc and cardiovascular risk factors. Our results showed 
a correlation between the logarithm of serum ucOC levels and sex (r = 0.191, p = 0.004). Women showed higher 
serum levels of ucOC than men (0.70 ± 0.33 ng/mL vs. 0.57 ± 0.33 ng/mL, p = 0.004). No association was found 
between ucOC levels and age (r = 0.041, p = 0.535).
When patients were further divided according to the presence of T2D, we found that serum ucOC levels were 
significantly lower in T2D patients than in MetS patients without T2D (Fig. 2A). To prevent possible biases in the 
results related to the potential influence of T2D on serum levels of ucOC, the group of patients with MetS with-
out T2D was analysed separately. In these patients, those presenting a higher cardiovascular risk (>P50 CV-ZS) 
showed significantly lower levels of ucOC than the group with lower cardiovascular risk (Fig. 2B). This trend 
remained close to significance after sex adjustment (0.65 ± 0.03 ng/mL vs. 0.75 ± 0.03 ng/mL; p = 0.074).
The association between circulating ucOC levels and cardiovascular risk factors showed a positive correlation 
between circulating levels of ucOC, HDL-C and total cholesterol and an inverse correlation between ucOC levels 
and WC, FPG, HbA1c and cardiovascular risk scores (CV-ZS, Framingham and REGICOR) in the entire sample. 
When T2D patients were excluded from the analysis, no association was found between ucOC and the variables 
related to glucose homeostasis (FPG and HbA1c). Nevertheless, the association between ucOC and WC, HDL-C, 
and cardiovascular risk scores remained significant (Table 2).
Relationship between serum levels of ucoc and cardiovascular risk. To determine the independent 
effect of circulating ucOC levels on cardiovascular risk expressed as CV-ZS (dependent variable), a multiple back-
ward model of linear regression analysis was performed adjusting for the effect of cardiovascular risk-associated 
variables (age, sex, smoking status and sedentarism) and medication (hypolipidaemic, antidiabetic and antihyper-
tensive drugs). These results showed that the only variables associated with CV-ZS were ucOC levels (B = −1.317, 
[−2.417/−0.217], p = 0.019) and hypolipidaemic drugs (B = −0.891, [−1.613/−0.169], p = 0.016), regardless of 
the effect of the other variables in MetS patients without T2D.
Evaluation of cardiovascular risk factors according to the 25th and 50th percentiles of ucoc 
serum levels. In order to establish the serum level of ucOC that determines significant differences in the met-
abolic profile and cardiovascular risk of the study population, MetS patients with and without T2D were divided 
into subgroups based on the percentiles of the ucOC levels. A comparative sex-adjustment study was performed 
according to the 25th and the 50th percentiles. Although statistically significant differences were found in some 
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risk factors when study groups were divided according to the 50th percentile, the largest differences were found 
when the 25th percentile was considered in the whole sample. Therefore, MetS patients below 25th percentile of 
ucOC serum levels showed a significantly worse cardiometabolic profile and higher cardiovascular risk in terms 
of cardiovascular risk scores (CV-ZS, Framingham and REGICOR).
This trend of worse cardiometabolic profile associated with lower levels of ucOC was maintained in MetS 
patients without prevalent T2D. However, significant differences were found only between ucOC and HDL-C. In 
a similar way that with the entire population, patients below the 25th percentile of ucOC serum levels had signifi-
cantly higher cardiovascular risk in terms of CV-ZS and REGICOR scores (Table 3).
Usefulness of ucOC serum levels to estimate the T2D risk in MetS patients. A logistic regression 
model was performed to assess the variables related to T2D risk in MetS patients. The independent varia-
bles included in the multiple logistic regression model were those anthropometric and biochemical variables 
Total sample (N = 235) <P50 CV-ZS (N = 117) >P50 CV-ZS (N = 118) p-value
Men/Women 111/124 52/65 65/59 0.394
Sedentarism (%) 44.7% 41.0% 48.3% 0.262
Current smoker (%) 11.1% 8.5% 13.6% 0.221
Presence of T2D (%) 22.6 11.2% 36.1% <0.001
Antidiabetic drugs (%) 23 12.0% 33.9% <0.001
Antihypertensive drugs (%) 75.3 70.1% 80.5% 0.064
Hypolipidaemic drugs (%) 37.4 41.9% 33.9% 0.207
mean SD mean SD mean SD
Age (years) 63.9 4.9 64.4 4.8 63.6 4.9 0.211
BMI (m/kg2) 32.5 3.5 30.9 2.9 34.0 3.4 <0.001
WC (cm) 107.7 10.2 102.9 8.4 112.4 9.6 <0.001
Mean BP (mm Hg) 103.3 11.4 99.4 9.8 107.2 11.6 <0.001
FPG (mg/dL) 102.3 25.3 91.5 12.2 113.0 30.0 <0.001
Total cholesterol (mg/dL) 202.3 36.9 206.8 36.1 197.8 37.2 0.062
HDL cholesterol (mg/dL) 49.1 10.0 53.4 9.8 44.8 8.3 <0.001
LDL cholesterol (mg/dL) 124.3 33.9 126.6 31.5 122.1 36.1 0.309
TG levels (mg/dL) 169.7 74.1 141.9 49.9 197.3 83.4 <0.001
HbA1c (%) 6.0 1.1 5.6 1.1 6.3 0.9 <0.001
ucOC (ng/mL) 5.9 5.1 6.9 6.0 4.9 3.7 0.004
Log ucOC (ng/mL) 0.6 0.3 0.7 0.3 0.6 0.3 <0.001
Framingham (%) 14.38 7.37 12.55 7.11 16.26 7.20 <0.001
REGICOR (%) 6.27 3.15 5.21 2.30 7.31 3.51 <0.001
Table 1. Anthropometric and biochemical parameters of the study population in the total sample according to 
P50 of CV-ZS. BMI: body mass index; WC: waist circumference; FPG: fasting plasma glucose; TG: triglyceride; 
T2D: type 2 diabetes; ucOC: undercarboxylated osteocalcin; CV-ZS: cardiovascular risk score. Data for continuous 
variables are expressed as mean ± SD. Data for categorical variables are expressed as percentages. Comparison 
was performed between groups with CV-ZS below and above P50. Student’s t test and χ2 test were used for 
comparisons of continuous and categorical variables, respectively, between groups. Significance was set at p < 0.05.
Figure 1. Scatter plots showing the correlation (Pearson’s test) between CV-ZS and REGICOR score (A) and 
between CV-ZS and Framingham score (B) in MetS patients.
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biologically linked to T2D development (age, sex, sedentarism, HDL-C and LDL cholesterol, TG levels, FPG 
and WC), in addition to ucOC levels categorised by the 25th percentile cut-off point of the total sample (2.53 ng/
mL). We found that the serum levels of ucOC were an independent estimator of T2D risk in patients with MetS 
(OR = 6.39, [2.51/16.27], p < 0.001) in addition to FPG levels (OR = 1.08, [1.05/1.10], p < 0.001).
A receiver operating curve (ROC) analysis was performed to assess the usefulness of serum levels of ucOC as 
a marker of T2D risk. Three different models were assessed. The first model included the main T2D risk factors 
(age, sex, WC, FPG, TG levels, HDL-C and LDL cholesterol) (Area under the curve (AUC) = 0.848; p < 0.001). 
The second model included only the logarithm of serum levels of ucOC (AUC = 0.727; p < 0.001). Finally, the 
model that combined serum levels of ucOC and T2D risk factors showed the highest AUC value (AUC = 0.894; 
p < 0.001) (Fig. 3).
Discussion
Our results show that ucOC serum levels are independently associated with cardiovascular risk determined as 
Z-score in MetS patients without prevalent T2D. We found that lower circulating levels of ucOC are related 
to worse metabolic profile and higher cardiovascular risk in MetS patients regardless of the presence of T2D. 
Furthermore, we found a relationship between serum levels of ucOC, sex, FPG and lipid profile in the whole pop-
ulation and with WC and HDL-C cholesterol in patients with MetS without T2D. Finally, serum levels of ucOC 
may act as an independent estimator of T2D risk in MetS patients.
The involvement of total OC and ucOC levels on energy metabolism and their close association with glucose 
and lipid metabolism has been largely studied21. Several studies described the inverse association between circu-
lating OC and the presence of T2D16,22,23, insulin resistance24,25, and measures of adiposity26. Most of the studies 
in MetS patients outlined the decrease in total OC levels in MetS patients compared to healthy subjects18,27–29. 
Nevertheless, other authors found no differences in total OC levels in postmenopausal women diagnosed with 
MetS compared to those without MetS23. Regarding ucOC levels, few data are available in patients with MetS.
Our findings showed lower ucOC serum levels in MetS patients at higher cardiovascular risk, regardless of 
the presence of T2D. Among patients with MetS, those with prevalent T2D showed worse cardiometabolic pro-
file and lower serum levels of ucOC. This finding is supported by validated cardiovascular risk scores, such as 
Figure 2. Bar graphs representing serum levels of ucOC in MetS patients with type 2 diabetes (+T2D) or without 
T2D (-T2D) (A) and in MetS patients without T2D based on the median distribution of CV-ZS (B). Data are 
represented as mean ± 95% confidence interval (CI). Student’s t test was used for comparisons between groups. 
Significance was set at p < 0.05.
Log ucOC Total sample Log ucOC MetS -T2D
r p r p
WC −0.163 0.014 −0.169 0.026
HDL cholesterol 0.281 <0.001 0.295 <0.001
FPG −0.186 0.005 −0.060 0.426
Total cholesterol 0.143 0.032 0.092 0.226
HbA1c −0.153 0.040 0.035 0.676
CV-ZS −0.225 0.001 −0.189 0.012
Framingham −0.308 <0.001 −0.191 0.022
REGICOR −0.192 0.004 −0.199 0.008
Table 2. Pearson correlation coefficients between serum levels cardiovascular risk factors and cardiovascular 
risk scores in the entire sample and in MetS patients without type 2 diabetes (-T2D). ucOC: undercarboxylated 
osteocalcin; WC: waist circumference; FPG: fasting plasma glucose; CV-ZS: cardiovascular risk score. 
Significance was set at p < 0.05.
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Framingham and REGICOR scores for the Spanish population, showing that patients above 50th percentile of car-
diovascular risk scores had lower ucOC levels and more unfavourable biochemical and anthropometric profiles. 
In consistency with our results, recent studies have reported lower serum levels of ucOC in T2D patients than in 
healthy subjects30 and lower in T2D patients with MetS than in those without MetS31.
MetS diagnosis implies an increase in cardiovascular risk32. However, a high variability of cardiovascular risk 
is found among these patients. Thus, within the MetS population, some patients are metabolically “healthier” 
than those with more unfavourable analytical and anthropometric values who would have worse prognosis. This 
fact makes difficult to categorise the cardiovascular risk in MetS patients. Despite tools to estimate cardiovascular 
risk, such as Framingham or REGICOR scores, are available, both of them present some limitations, such as the 
non-inclusion of important risk parameters, such as WC, the variability of parameters included depending on the 
calculator used, the loss of cases due to the lack of qualifying options, or the subjectivity of patients, among others. 
Therefore, these tools have been used primarily for epidemiological studies. In this way, it would be very useful to 
have a tool based on the diagnostic criteria of MetS reflecting the “metabolic” cardiovascular risk regardless of the 
risk due to environmental factors, such as lifestyle and the current medication (“acquired” cardiovascular risk).
In this regard, we calculated a CV-ZS to homogenise and to stratify the cardiovascular risk in this population 
considering the risk factors for MetS diagnostic accepted by the US National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP III)33. This score shows a close correlation with validated cardiovascular 
risk scores, such as Framingham and REGICOR.
The relationship between total OC levels and cardiovascular parameters has been previously explored showing 
an association between lower serum levels of OC and atherosclerotic parameters in patients with T2D8,34 and 
myocardial infarction in young patients35, as well as a lower mortality rate associated with increased total OC 
levels36.
In the MetS population, some studies associate lower levels of total OC with cardiovascular risk parame-
ters30,37,38 and with abdominal aortic calcification in men39.
Although some studies have linked ucOC levels to the risk of MetS through its relationship with individ-
ual cardiovascular risk factors18,40–42; to date, no studies evaluating the role of circulating ucOC as estimator of 
generalised cardiovascular risk in MetS patients are available. Our results show that ucOC serum levels could 
be an important estimator affecting cardiovascular risk expressed as CV-ZS, after adjusting by lifestyle and 
medication-related variables, only in those MetS patients who do not meet T2D criteria. This result could be 
Total sample
P25 of ucOC levels P50 of ucOC levels
<2.53 ng/mL (n = 57) ≥2.53 ng/mL (n = 170)
p
<4.58 ng/mL (n = 114) ≥4.58 ng/mL (n = 113)
pmean SD mean SD mean SD mean SD
BMI 32.73 3.37 32.41 3.61 0.535 32.58 3.23 32.41 3.85 0.701
WC 109.78 9.80 106.88 10.27 0.260 108.77 10.01 106.44 10.31 0.353
mean BP 103.74 12.16 103.17 11.15 0.819 103.25 11.26 103.38 11.56 0.488
HDL cholesterol 45.35 7.79 50.76 10.28 0.002 47.31 9.13 51.52 10.39 0.009
FPG 111.63 34.29 99.05 20.86 0.001 106.11 28.16 98.27 21.76 0.013
TG 192.19 98.63 162.47 63.88 0.008 178.17 82.87 161.63 65.51 0.090
HbA1c 6.33 0.99 5.84 1.08 0.006 6.09 0.94 5.86 1.19 0.126
CV-ZS 1.06 3.38 −0.40 2.41 0.000 0.42 2.95 −0.49 2.47 0.011
Framingham 17.56 8.29 13.19 6.75 0.001 15.66 8.01 12.84 6.41 0.015
REGICOR 7.11 4.01 5.95 2.74 0.055 6.67 3.55 5.80 2.61 0.133
MetS – T2D group
P25 of ucOC levels P50 of ucOC levels
<3.00 ng/mL (n = 44) ≥3.00 ng/mL (n = 131)
p
4.91 ng/mL (n = 88) ≤4.91 ng/mL (n = 87)
pmean SD mean SD mean SD mean SD
BMI 32.75 3.16 32.37 3.73 0.743 32.57 3.32 32.40 3.82 0.697
WC 109.79 9.81 106.51 10.26 0.277 108.50 9.75 106.49 10.70 0.959
mean BP 104.64 11.53 102.64 11.29 0.421 103.46 11.49 103.12 11.32 0.789
HDL cholesterol 45.92 7.86 51.16 10.49 0.006 47.73 9.24 51.53 10.52 0.038
FPG 109.54 31.18 98.52 21.14 0.509 105.29 27.02 98.29 22.79 0.167
TG 184.22 93.15 162.74 63.14 0.196 176.57 80.90 161.50 66.27 0.162
HbA1c 6.19 0.97 5.86 1.12 0.438 6.04 0.90 5.89 1.26 0.373
CV-ZS 0.96 3.15 −0.53 2.39 0.010 0.31 2.91 −0.47 2.49 0.097
Framingham 16.57 8.15 13.17 6.75 0.726 15.50 7.82 12.71 6.50 0.481
REGICOR 7.03 3.82 5.85 2.67 0.029 6.54 3.44 5.86 2.68 0.353
Table 3. Comparison of cardiovascular risk parameters according to the 25th and 50th percentiles (P25 and 
P50, respectively) of serum ucOC logarithm by sex-adjusted univariate analysis of variance. BMI: body mass 
index; WC: waist circumference; FPG: fasting plasma glucose; TG: triglyceride; ucOC: undercarboxylated 
osteocalcin; CV-ZS: cardiovascular risk score. Data for continuous variables are expressed as mean ± standard 
deviation (SD). Univariate analysis of variance using a general linear factorial model adjusted by sex was used 
for comparisons between quantitative variables. Significance was set at p < 0.05.
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explained because the presence of diabetes is one of the major determinants of cardiovascular risk rather than OC 
levels. In consistency with our results, some studies have shown that a higher ratio of circulating ucOC/OC was 
independently associated with lower incidence of myocardial infarction in older men43. Contrary to our results, a 
cross-sectional study including 162 Korean subjects showed a relationship between higher serum levels of ucOC 
and coronary artery calcification44. These differences could be due to the fact that their study population included 
also diabetic patients, but no adjustment for the presence of diabetes or any type of medication was performed.
The association between ucOC levels and cardiovascular risk could be explained, in part, by its relationship 
with some cardiovascular factors, such as WC, HDL-C, total cholesterol, FPG and HbA1c. In MetS patients with-
out T2D, HDL-C was the main variable associated with serum ucOC levels. These relationships have been previ-
ously reported in other studies16,30,31. One of these studies suggested that higher levels of HDL-C could influence a 
higher OC production16. According to this, higher levels of ucOC found in MetS patients with lower CV-ZS could 
be related to higher levels of HDL-C.
Our results showed an association between serum levels of ucOC and sex, being these levels higher in women 
than men, in consistency with the previously reported45. However, the cause of this sex-based difference has not 
been explored yet. We suggest that higher ucOC levels found in women could be explained by the increase in 
bone resorption leading to bone loss during menopause. Bone degradation could increase serum levels of ucOC. 
An alternative hypothesis that we suggest states that increased levels of ucOC may act as a compensatory mecha-
nism to restore bone homeostasis in postmenopausal women.
In contrast with the studies reporting an association between OC and ucOC levels and age46,47, we found no 
association in our study population, neither for men nor for women. Accordingly, De Pergola et al., also found no 
association between serum levels of OC and age neither in obese nor in T2D patients16. The lack of association 
between ucOC levels and age could be due to the restricted inclusion criteria on age, since our study population 
aged 55–75 years.
Based on the inverse and independent association between serum ucOC levels and CV-ZS found in our study, 
we determined that MetS patients with serum ucOC values below 2.53 ng/mL would have a worse metabolic 
profile than those with levels above this cut-off point. This trend was maintained for the group of MetS patients 
without prevalent T2D, but significant differences were found only for HDL-C levels. As expected, all patients 
below this cut-off point had significantly higher cardiovascular risk in terms of CV-ZS and REGICOR related to 
lower ucOC levels, regardless of diabetes.
We suggest that the measurement of ucOC serum levels could be useful for the estimation of cardiovascular 
risk in MetS patients. Accordingly, Alfadda A. et al.31 suggested that ucOC levels could play a role in the evalua-
tion of the cardiovascular risk in patients with T2D due to the multiple associations found between ucOC levels 
and individual cardiovascular risk factors. However, this is the first study that determines an unified Z-score 
including the main cardiovascular risk factors to classify MetS patients according to their “metabolic” cardiovas-
cular risk.
Figure 3. ROC curve for the usefulness of ucOC level as an estimator of T2D in MetS patients. (a) age, sex, 
WC, FPG, TG levels, HDL and LDL cholesterol; AUC = 0.848; p < 0.001. (b) logarithm of ucOC serum levels; 
AUC = 0.727; p < 0.001. (c) age, sex, WC, FPG, TG levels, HDL and LDL cholesterol + log ucOC serum levels; 
AUC = 0.894; p < 0.001. T2D: type 2 diabetes; WC: waist circumference; FPG: fasting plasma glucose; TG: 
triglyceride; ROC: receiver operating curve; AUC: area under the curve.
7Scientific RepoRtS |         (2020) 10:1840  | https://doi.org/10.1038/s41598-020-58760-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additionally, MetS patients have a larger risk of developing T2D associated with their metabolic profile. The 
association between ucOC levels and glucose homeostasis is consistent and there is a large evidence reporting the 
role of ucOC as a regulator of glucose and energy metabolism48,49. Higher levels of this protein have been related 
to an improvement in insulin sensitivity and secretion due to the direct action of ucOC on adipocytes and β-cell 
mass50. As above mentioned, within a population of MetS patients, there are patients at higher risk than others to 
become diabetic patients depending on their metabolic profile. Considering ucOC levels as an independent var-
iable in conjunction with biological variables related to T2D development, we found that the risk of T2D devel-
opment in MetS patients with ucOC serum levels below 2.53 ng/mL was 6-fold higher than in those with serum 
levels of ucOC above this value. Our ROC curve analysis revealed that the inclusion of ucOC serum levels in 
addition to age and T2D-related variables, improves the prediction model for T2D risk in MetS patients. Similarly, 
to our results, Villafan-Bernal et al. used the ucOC/OC index to predict the probability of having T2D in a cohort 
of T2D patients and healthy subjects. Patients with ucOC/OC index below 0.31 had 12.6-fold increased prob-
ability of developing T2D than patients with higher index51. These findings strengthen our above-mentioned 
results, suggesting that serum levels of ucOC could be a potential biomarker to estimate cardiovascular and T2D 
risk in MetS patients. In addition, based on the aforementioned evidences, in the future, ucOC might become a 
therapeutic target to prevent cardiovascular events as reported by recent studies conducted in animal models52,53.
Our study has certain limitations. First, the cross-sectional design precludes any determination of causality 
in our findings. Second, we did not measure total OC, N-MID OC or other factors that could affect serum levels 
of ucOC, such as vitamins D and K, which would add valuable information to our results. Third, the collection 
of sedentary lifestyle data was recorded using a self-administered questionnaire, which implies the possibility of 
bias. Finally, since our study was conducted in a specific population of MetS patients, we cannot ascertain that the 
same results would be found in other ethnic or study groups.
The strengths of this study lie on the novel evaluation of cardiovascular risk in MetS patients using a global 
and unified score of accepted MetS risk factors, allowing thus a better characterisation of the cardiovascular risk 
in this heterogeneous population. In addition, we have considered potential confounders, such as the presence of 
T2D and the most commonly used medication in MetS patients.
To our knowledge, this is the first study showing a robust relationship between serum levels of ucOC and cardio-
vascular risk score. Moreover, the large sample size provides sufficient statistical power giving robustness to our results.
In summary, we suggest that circulating ucOC levels could be an estimator of the cardiovascular risk in MetS 
patients without T2D. In addition, lower serum levels of ucOC could contribute to T2D development. The meas-
urement of circulating ucOC levels could become a strategy to identify MetS patients at high risk in order to 
establish preventive and therapeutic approaches. These findings break new ground for new research lines to eval-
uate the role of ucOC as a biomarker and as a potential therapeutic target, as well as the usefulness of CV-ZS in 
clinical practice in future longitudinal studies.
Methods
Study population. A cross-sectional study was conducted in 235 patients with MetS, aged 55–75 years 
(53.2% women). All patients included were overweight or obese (BMI ≥ 27 kg/m²) and met at least three diagnos-
tic criteria for MetS: high BP, impaired FPG level, high TG level, low HDL-C level and increased WC according 
to the definitions of the NCEP ATP III33. A total of 21.8% of the study patients had prevalent T2D, diagnosed 
according to the American Diabetes Association criteria.
From December 2014 to December 2016, patients were consecutively recruited at primary healthcare centres 
in Granada (Spain). All patients were Caucasian outpatients, and they did not present any prevalent cardiovas-
cular disease, cancer, morbid obesity (≥40 kg/m²), and/or presence of bone diseases that could interfere with 
the study protocol. None of them had been treated with calcium or vitamin D supplements, hormone therapy, 
anti-osteoporotic drugs, steroids, vitamin K antagonists, thiazolidinediones, glucocorticoids or other medications 
that might affect bone metabolism.
The study was conducted with the approval of the ethics committee of the San Cecilio University Hospital of 
Granada and conformed to the principles of the World Medical Association’s Declaration of Helsinki. Written 
informed consent was obtained from all patients.
clinical and anthropometric evaluation. Anthropometric data were collected according to standard 
procedures. The BMI was calculated using the Quetelet formula (weight in kilograms divided by the square of 
height in meters); WC was measured midway between the superior border of the iliac crest and the lowest rib. 
Systolic BP (SBP) and diastolic BP (DBP) were obtained using a standard mercury sphygmomanometer (12 cm 
long and 35 cm wide). The mean BP was calculated using the equation (2 x DBP + SBP)/3)54.
Patients reported smoking status and level of physical activity by using a specific health questionnaire. 
Smoking status was categorised as non-smoker or current smoker. Physical activity was recorded using a specific 
questionnaire in which study patients reported how many hours used to spend on each activity throughout the 
day. Based on the results, the study sample was divided into two groups: sedentary (more than 7 hours sitting per 
day) and non-sedentary (less than 7 hours sitting per day).
Biochemical measurements. Blood samples were collected after an overnight fast. Conventional anal-
yses of lipid profile (total cholesterol, HDL-C, LDL-cholesterol and TG level), FPG and glycated haemoglobin 
(HbA1c) were determined at the Clinical Analysis Unit of San Cecilio University Hospital of Granada. The lev-
els of ucOC were measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
instructions (Takara Bio, Japan). All measurements were determined in duplicate at our laboratory. Precision 
testing was performed by the determination of intra-assay and inter-assay variations (6% and 10%, respectively), 
which were consistent with those reported by the manufacturer (5.21% and 8.33%, respectively).
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calculation of cardiovascular risk scores. A Z-score of the combined cardiovascular risk factors used 
for the diagnosis of MetS (CV-ZS) was calculated including WC, mean BP, HDL-C, TG levels, and FPG according 
to the NCEP ATP III. The Z-score of each cardiovascular risk factor was calculated using the mean and standard 
deviation (SD) by applying the equation (x – mean (x))/SD), being x the variable of interest. The mean-centring 
and SD normalisation were sex-specific for each variable. The CV-ZS was the average of the Z-scores of TG levels, 
FPG, WC, mean BP and the inverse Z-score of HDL-C55,56.
In order to correlate the CV-ZS with other validated cardiovascular risk scores, the Framingham and 
REGICOR (for Spanish population) scores were estimated according to the equation described by Wilson P.W. et 
al.57 and through the online calculator available at www.imim.cat/ofertadeserveis/software-public/regicor/?158, 
respectively. Both scores include age, sex-adjusted cardiovascular risk variables (total cholesterol, HDL-C and SBP 
and DBP), and presence of diabetes and tobacco consumption (both variables collected using a questionnaire).
Statistical analysis. Analyses were performed using SPSS version 22.0 software (SPSS, Inc., Chicago, IL). 
Continuous variables were expressed as mean ± SD, and categorical variables were expressed as percentages. 
Kolmogorov-Smirnov test was used to test the normality of the variables. A log transformation was performed 
for skewed variables. Comparisons of continuous variables among groups were performed using the unpaired 
Student’s t test. When the comparison between groups required an adjustment by covariates, a univariate analysis 
of variance using a general linear factorial model was constructed. The χ2 test was used to compare categorical 
variables between groups.
Associations between continuous variables were described by the Pearson’s correlation coefficient. Multiple 
linear regression analysis was performed to identify the variables influencing cardiovascular risk (dependent 
variable). The independent variables used were those potentially related to cardiovascular risk, such as age, sex, 
smoking status, sedentarism and related medication (hypolipidaemic, antidiabetic and antihypertensive drugs).
In order to identify ucOC as an independent predictor of T2D, a multiple logistic regression model was per-
formed. The usefulness of serum ucOC levels as a marker of T2D risk was analysed using a ROC curve. The AUC 
indicates the probability to predict an event. AUC values above 0.75 indicate a good predictive performance59.
Statistical significance was set at p < 0.05 (two tailed) and p < 0.10 for multiple linear regression analysis.
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